Neuroprotective potential of a TrkB-FL-derived cell-penetrating peptide in cochlear synaptopathy and noise-induced hearing loss.
MTFL457, a TrkB-FL-derived cell-penetrating peptide, just put up strong numbers against noise-induced hearing loss in new research out of Madrid. Researchers tested MTFL457 in both ex vivo cochlear explants and in vivo mouse models hammered by excitotoxicity and loud noise—two key contributors to synaptic damage and hearing loss.
Mol Med
by Torres-Campos E, Varela-Nieto I, Díaz-Guerra M
“Neuroprotective potential of a TrkB-FL-derived cell-penetrating peptide in cochlear synaptopathy and noise-induced hearing loss. Torres-Campos E(1), Varela-Nieto I(2)(3)(4), Díaz-Guerra M(5). Author information: (1)Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Arturo Duperier, 4, Madrid, 28029, Spain. (2)Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Arturo Duperier, 4, Madrid, 28029, Spain. i.varela.nieto@csic.es. (3)Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, 28029, Spain. i.varela.nieto@csic.es. (4)Instituto de Investigación Sanitaria del Hospital La Paz (IdiPAZ), Madrid, 28046, Spain. i.varela.nieto@csic.es. (5)Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Arturo Duperier, 4, Madrid, 28029, Spain. mdiazguerra@iib.uam.es. BACKGROUND: Noise-induced hearing loss (NIHL) is the second leading cause of deafness globally. However, effective pharmacological treatments remain unavailable. Excitotoxicity, an early NIHL event, is a central mechanism in degeneration of cochlear synapses established between inner hair cells (IHCs) and spiral ganglion neurons (SGNs). This excitotoxic damage can trigger the degradation of the neurotrophic TrkB receptor, thereby inhibiting brain-derived neurotrophic factor (BDNF) signaling and challenging neurotrophin-based therapies for hearing loss. METHODS: We employed an ex vivo model of excitotoxicity, where excitotoxicity was induced in cochlear explants by overstimulation of excitatory glutamate receptors, and an in vivo model of noise overexposure. The effects of excitotoxicity on the neurotrophic system and cell architecture were established by immunohistochemistry. Hearing function was evaluated in vivo by the auditory brainstem responses (ABR) test, performed before and after noise overexposure. RESULTS: In this study, we evaluated the therapeutic potential in the inner ear of MTFL457, a cell-penetrating peptide designed to prevent TrkB-FL degradation in brain excitotoxicity. MTFL457 showed efficient distribution across cochlear cell types in both ex vivo and in vivo models, supporting its ability to reach the inner ear and suggesting that it can cross the blood-labyrinth barrier after systemic administration. In explants undergoing excitotoxicity, MTFL457 prevented TrkB-FL dysregulation, partially restored downstream prosurvival signaling, and significantly reduced neuronal damage and features associated with cochlear synaptopathy. In vivo, despite known sex-dependent differences in susceptibility to noise-induced damage, treatment with MTFL457 preserved auditory function and synaptic integrity in both males and females, although the magnitude of protection varied between sexes. Together, these findings support a protective effect of MTFL457 in models of excitotoxic cochlear injury. CONCLUSIONS: These results support the therapeutic potential of peptide MTFL457 for treatment of NIHL and possibly other types of sensorineural hearing loss likewise associated with excitotoxicity. © 2026. The Author(s). Conflict of interest statement: Declarations. Ethics approval: This study has no human data. Animal studies were approved by ethics committees from Consejo Superior de Investigaciones Científicas (CSIC) and Comunidad de Madrid (Ref PROEX 325.4/21) and comply with European (2010/63/EU) and Spanish (RD 53/2013) regulations. Consent for publication: N/A. Competing interests: The authors declare no competing interests.”
Why does this matter? Noise-induced hearing loss is everywhere and remains stubbornly untreatable. The problem starts with excitotoxicity: glutamate overload damages the synapses connecting inner hair cells and spiral ganglion neurons, which leads to the breakdown of the TrkB receptor. That’s a big deal, since TrkB is crucial for BDNF signaling and neuronal survival. Most neurotrophin-based approaches hit a wall because of this early receptor loss.
Here’s where MTFL457 stands out:
The peptide distributed efficiently across cochlear cell types, both in organ cultures and living animals.
It crossed the blood-labyrinth barrier after systemic administration—no need for direct inner ear injection.
MTFL457 prevented TrkB-FL degradation, kept prosurvival signals alive, and slashed neuronal damage in excitotoxic explants.
In noise-exposed mice, MTFL457 preserved hearing function and synaptic integrity in both males and females.
Sex-based differences in damage and peptide response did show up, but protection was clear in both groups. The main takeaway: MTFL457 supports the idea that targeted peptides can protect cochlear synapses and auditory function where small molecules have failed.
This is a solid win for the peptide research community. It’s more evidence that rationally designed peptides can do what traditional compounds can’t—cross barriers, stabilize key proteins, and rescue cell function. For anyone exploring peptide-based approaches to neuroprotection, this study is worth a close read. Browse the peptide research index for more breakthroughs in the field.
The future of inner ear research just got a lot more interesting.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.